Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität

 

 Permissions and Reprints

Zusammenfassung

Hintergrund: Trotz ihrer großen medizinischen und ökonomischen Bedeutung wurden zur Psoriasis vulgaris (Pso) in Deutschland bisher nur wenige bevölkerungsbezogene Daten erhoben.

Material und Methoden: In einer webbasierten Gesundheitsstudie (NHWS = National Health and Wellness Survey) wurden 2007 bundesweit erwachsene Pso-Patienten und Nicht-Betroffene zu medizinischer Ressourcennutzung, Arbeitsproduktivität und gesundheitsbezogener Lebensqualität (LQ) befragt.

Ergebnisse: Von den 15 000 Befragten gaben 382 Personen (2,5 %) die ärztlich bestätigte Diagnose Pso an. Davon waren 72 % (n = 264) von einer leichten und 28 % (n = 118) von einer mittelschweren oder schweren Form betroffen. Befragte mit mittelschwerer/schwerer Pso nahmen in stärkerem Umfang die Ressourcen des Gesundheitssystems in Anspruch. Außerdem hatten diese fast doppelt so hohe eigene finanzielle Aufwendungen. Ihre Arbeitsproduktivität sowie ihre LQ waren signifikant vermindert.

Schlussfolgerung: Pso führt zu erhöhten Ressourcenverbräuchen im Gesundheitssystem, verminderter Lebensqualität und reduzierter Arbeitsproduktivität. Diese Krankheitsfolgen sind für die Therapieplanung und Versorgung von großer Bedeutung.

Abstract

Data of the 2007 web-based NHWS (National Health and Wellness Survey) have been evaluated regarding the prevalence, utilisation of health care resources, work productivity and burden of disease in psoriasis (pso) patients compared to non-affected responders. Based on the NHWS, 382 out of 15 000 respondents reported being diagnosed with pso by a physician. This reflects a prevalence of 2.5 % and project to approximately 1.9 million adults affected by pso in Germany. Particularly patients with moderate/severe pso were found to take more advantage of the health care system, to have higher out-of-pocket-expenses and reduced work productivity. Health-related quality of life was substantially reduced. These aspects are important when deciding on the adequate therapy.

Literatur

• 1 Augustin M, Glaeske G, Radtke M A et al. Epidemiology and comorbidity of psoriasis in children.  Br J Dermatol. 2010;  162 (3) 633-636
  CrossrefPubMedGoogle Scholar
• 2 Augustin M, Krüger K, Radtke M A, Schwippl I, Reich K. Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Prospective Cross-Sectional Study in Germany.  Dermatology. 2008;  216 366-372
  CrossrefPubMedGoogle Scholar
• 3 Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Comorbidity and age-related prevalence of psoriasis – analysis of health insurance data in Germany.  Acta Derm Venereol. 2010;  90 147-151
  CrossrefPubMedGoogle Scholar
• 4 Augustin M, Reich K, Reusch M et al. Health services research in psoriasis – the German approach.  Dermatology. 2009;  218 (4) 293-301
  CrossrefPubMedGoogle Scholar
• 5 Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.  J Dtsch Dermatol Ges. 2005;  3 (7) 511-518
  CrossrefPubMedGoogle Scholar
• 6 Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe; 1998
  Google Scholar
• 7 Consumer Health Sciences (CHS) .Im Internet: http://www.chsinternational.com Stand: 15.09.2009
• 8 Delfino M, Holt E W, Taylor C R, Wittenberg E, Qureshi A A. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study.  J Am Acad Dermatol. 2008;  59 (3) 439-447
  CrossrefPubMedGoogle Scholar
• 9 Jiménez-Puya R, Gómez-García F, Amorrich-Campos V, Moreno-Giménez J C. Etanercept: Efficacy and safety.  J Eur Acad Dermatol Venereol. 2009;  23 (4) 402-405
  CrossrefPubMedGoogle Scholar
• 10 Gelfand J M, Troxel A B, Lewis J D et al. The risk of mortality in patients with psoriasis: results from a population-based study.  Arch Dermatol. 2007;  143 (12) 1493-1499
  CrossrefPubMedGoogle Scholar
• 11 Griffiths C EM, Camp R DR, Barker J NWN. Rook's textbook of dermatology. 7th ed. Oxford: Blackwell; 2005
  Google Scholar
• 12 Kimball A B, Jacobson C, Weiss S, Vreeland M G, Wu Y. The psychosocial burden of psoriasis.  Am J Clin Dermatol. 2005;  6 (6) 383-92
  CrossrefPubMedGoogle Scholar
• 13 Krüger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.  Arch Dermatol. 2001;  137 (3) 280-284
  PubMedGoogle Scholar
• 14 Krüger G G, Feldman S R, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?.  J Am Acad Dermatol. 2000;  43 (2 Pt 1) 281-5
  CrossrefPubMedGoogle Scholar
• 15 Kurd S K, Gelfand J M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003 – 2004.  . 2009;  60 (2) 218-24
  PubMedGoogle Scholar
• 16 Mrowietz U, Elder J T, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.  Arch Dermatol Res. 2006;  298 (7) 309-319
  CrossrefPubMedGoogle Scholar
• 17 Nast A et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris.  J Dtsch Dermatol Ges. 2011; 
  PubMedGoogle Scholar
• 18 Nelson A A, Pearce D J, Fleischer A B, Balkrishnan R, Feldman S R. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.  J Am Acad Dermatol. 2008;  58 (1) 125-35
  CrossrefPubMedGoogle Scholar
• 19 Official figures by the Federal Statistical Bureau on average stays in rehabilitation care in the ICD 10 code L40. Im Internet: http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/i95479111/47809735 Stand: 15.09.2009
  Google Scholar
• 20 Radtke M A, Augustin M. Effiziente Kontrolle erforderlich. Kosten und Wirtschaftlichkeit der Psoriasis-Therapie.  Gesellschaftspolitische Kommentare. 2008;  1 26-29
  PubMedGoogle Scholar
• 21 Radtke M A, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey.  J Eur Acad Dermatol Venereol. 2009;  23 (6) 683-91
  CrossrefPubMedGoogle Scholar
• 22 Radtke M, Reich K, Reich C et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis: development of a new system of quality indicators.  Dermatology. 2009;  219 (1) 54-8
  CrossrefPubMedGoogle Scholar
• 23 Rapp S R, Feldman S R, Exum M L, Fleischer Jr A B, Reboussin D M. Psoriasis causes as much disability as other major medical diseases.  J Am Acad Dermatol. 1999;  41 (3 Pt 1) 401-7
  CrossrefPubMedGoogle Scholar
• 24 Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.  Br J Dermatol. 2009;  160 (5) 1040-7
  CrossrefPubMedGoogle Scholar
• 25 Reilly M C, Zbrozek A S, Dukes E M. The validity and reproducibility of a work productivity and activity impairment instrument.  Pharmacoeconomics. 1993;  4 (5) 353-365
  CrossrefPubMedGoogle Scholar
• 26 Revicki D A, Menter A, Feldman S et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.  Health Qual Life Outcomes. 2008;  6 75
  CrossrefPubMedGoogle Scholar
• 27 Schäfer I, Hacker J, Rustenbach S J et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.  Eur J Dermatol. 2010;  20 (1) 62-67
  PubMedGoogle Scholar
• 28 Schäfer I, Rustenbach S J, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany.  Dermatology. 2008;  217 (2) 169-172
  CrossrefPubMedGoogle Scholar
• 29 Schmid-Ott G, Künsebeck H W, Jäger B et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women.  Acta Derm Venereol. 2005;  85 (1) 27-32
  Google Scholar
• 30 Schöffski O, Augustin M, Prinz J et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.  J Dtsch Dermatol Ges. 2007;  5 (3) 209-218
  PubMedGoogle Scholar
• 31 Sizto S, Bansback N, Feldman S R, Willian M K, Anis A H. Economic evaluation of systemic therapies for moderate to severe psoriasis.  Br J Dermatol. 2009;  160 (6) 1264-72
  CrossrefPubMedGoogle Scholar
• 32 Sohn S, Schöffski O, Prinz J et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.  Dermatology. 2006;  212 (2) 137-144
  CrossrefPubMedGoogle Scholar
• 33 Stern R S, Nijsten T, Feldman S R et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.  J Investig Dermatol Symp Proc. 2004;  9 136-139
  CrossrefPubMedGoogle Scholar
• 34 United States Census Bureau and Organization for Economic Cooperation and Development, International Database (2007) .Im Internet: http://www.census.gov Stand: 20.08.2009
• 35 Ware J E, Kosinski M, Turner-Bowker D M, Gandek B. How to score Version 2 of the SF-12^® Health Survey (with a supplement documenting version 1).  Health Assessment Lab. 2002; 
  PubMedGoogle Scholar
• 36 Zachariae R, Zachariae C, Ibsen H H, Mortensen J T, Wulf H C. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients.  . 2002;  84 (3) 205-212
  PubMedGoogle Scholar

Dr. med. Univ.-Prof. Matthias Augustin

Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm)
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)
Universitätsklinikum Hamburg-Eppendorf

Martinistr. 52
20246 Hamburg

Email: m.augustin@uke.de